Business Wire

IL-SEVAN

Share
Sevan Certified as National Veteran Owned Business

Sevan Multi-Site Solutions, Inc. (Sevan ) has earned the exclusive designation as a Certified Veteran’s Business Enterprise™ (VBE) from the National Veteran-Owned Business Association (NaVOBA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005984/en/

Sevan, a global leader in innovative program management for clients with multiple sites, partnered with NaVOBA to receive the certification—which creates corporate contracting opportunities for veteran and service-disabled veteran businesses through certification, advocacy, outreach, recognition and education.

“Sevan is honored to be a Certified Veteran’s Business Enterprise™ via the National Veteran-Owned Business Association,” said Jim Evans, Founder and CEO of Sevan. “As a West Point graduate and former special forces officer, it’s a privilege to receive this designation. We greatly look forward to additional partnerships with other veteran owned organizations and clients across the restaurant, retail and government spaces.”

To be eligible for certification, organizations must be at least 51% owned, operated and controlled by one or more U.S. military veterans.

“Sevan becoming a Certified Veteran’s Business Enterprise™ is an incredibly exciting milestone for our team and organization,” said David Hendrix, Chief Commercial Officer. “Many of our clients are looking to maximize their diverse spend goals. Sevan now qualifies as a diverse supplier. We look forward to partnering with our current and new clients with this stamp of approval to contribute to our nation’s overall diverse spend initiatives.”

The certification process included a comprehensive list of business requirements and criteria, along with a rigorous examination and verification process. Certification enables Sevan to be more unique and competitive in the multi-site space.

“Corporations will not risk the accuracy of their Supplier Diversity spending goals by recording spend on contracts with firms that say they are owned by veterans if they aren’t absolutely certain of the ownership, operation and control of that firm,” said NaVOBA President Matthew Pavelek. “Working with a third-party nonprofit organization like NaVOBA and its VBE certification program provides that certainty.”

In 2022, Sevan was recognized as an Employee-Rated Great Place to Work® for the 9th consecutive year. In 2021, Sevan ranked on the Inc. 5000 list of the nation’s fastest-growing private companies for the 4th consecutive year. Also in 2021, Sevan ranked No. 21 on Engineering News-Record (ENR)’s Top 50 Program Management Firms, No. 44 on ENR’s Top 100 Construction Management-for-Fee Firms and earned the Gold HIRE Vets Medallion Award. In 2020, Sevan ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Visit our website to learn more about Sevan.

About Sevan

Sevan is an innovative global leader in design, program management, construction services and data analytics for organizations with multiple sites. Sevan puts capital to work—creating speed and scale—via dramatically enhanced efficiencies and accelerated schedules for high-quality program rollouts to maximize ROI. We partner with some of the world’s biggest brands and serve the unique needs of clients in the restaurant, retail and government spaces and create unlimited value. Sevan’s team spans across four countries and 40 states. As an extension of your team, our in-house experts manage capital improvement initiatives through every step of a program’s lifecycle.

Sevan helps iconic brands optimize their multi-site construction and facility programs in the United States and internationally. Sevan is headquartered near Chicago in Downers Grove, Illinois and has an international office in London.

Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan strategically guides worldwide brands—including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Carbon Health, Chipotle, Corvias, DaVita, Department of Veteran Affairs, Focus Brands, HCA Healthcare, HEB, Inspire Brands, Jiffy Lube, Kroger, Luxottica, McDonald’s, Motor Fuel Group, Office Depot, Popeyes, QDOBA, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart, WOW Carwash and Yum! Brands—through their entire turnkey program lifecycle. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 25,000 retail stores, 17,000 restaurants and 32,000 healthcare sites. The team has also completed more than 32,000 surveys, totaling more than 1 billion square feet. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients.

To learn more about Sevan’s offerings, visit www.sevansolutions.com .

For more information, please contact Hafsa Mahmood by calling 708.723.3849 or via e-mail at hafsa.mahmood@sevansolutions.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye